Literature DB >> 31580537

Silencing transcription factor FOXM1 represses proliferation, migration, and invasion while inducing apoptosis of liver cancer stem cells by regulating the expression of ALDH2.

Lijian Chen1, Meiyun Wu2, Chunyi Ji1, Miaoxian Yuan1, Chaoyang Liu1, Qiang Yin1.   

Abstract

OBJECTIVE: This study is performed to explore the role of transcription factor FOXM1 in promoting the self-renewal and proliferation of liver cancer stem cells (LCSCs) by regulating the expression of acetaldehyde dehydrogenase-2 (ALDH2).
METHODS: CD133+ CD24+ LCSCs were sorted and identified. A series of experiments were carried out to determine the proliferation, colony formation rate, migration, invasion, and apoptosis of LCSCs after interfering with FOXM1. Proliferation-, epithelial-mesenchymal transition (EMT)-, apoptosis-, and stemness-related factors were then detected by western blot analysis. Tumor xenograft in nude mice was used to figure out the role of FOXM1 in tumorigenesis in vivo by regulating ALDH2 expression. Luciferase activity assay was conducted to determine whether FOXM1 could target ALDH2 promoter region and thereby affecting ALDH2 expression.
RESULTS: The sorted CD133+ CD24+ Huh-7 cells had the characteristic of stem cells. FOXM1 was highly expressed in CD133+ CD24+ Huh-7 cells. Silencing FOXM1 inhibited the proliferation and colony formation of LCSCs and decreased the expression of proliferating cell nuclear antigen and Ki-67 protein; inhibited the migration, invasion, and EMT of LCSCs while promoting the apoptosis of LCSCs, as well as promoted the expression of Bax and cleaved-caspase-3, and inhibited the expression of Bcl-2. Silencing FOXM1 inhibited the expression of Nanog, Oct4, and Sox2 in LCSCs by decreasing the expression of ALDH2. in vivo experiment, silencing FOXM1 suppressed tumorigenesis of LCSCs by decreasing the expression of ALDH2.
CONCLUSION: Our study provides evidence that silencing FOXM1 inhibits stemness of LCSCs by decreasing the expression of ALDH2, and represses the proliferation, migration, invasion, and tumorigenesis while inducing the apoptosis of LCSCs.
© 2019 International Union of Biochemistry and Molecular Biology.

Entities:  

Keywords:  ALDH2; FOXM1; liver cancer stem cells; self-renewal; transcription factor

Year:  2019        PMID: 31580537     DOI: 10.1002/iub.2166

Source DB:  PubMed          Journal:  IUBMB Life        ISSN: 1521-6543            Impact factor:   3.885


  6 in total

1.  miR-4429 Regulates the Proliferation, Migration, Invasion, and Epithelial-Mesenchymal Transition of Cervical Cancer by Targeting FOXM1.

Authors:  Lin Liang; Yu Wei Zheng; Yan Li Wang
Journal:  Cancer Manag Res       Date:  2020-07-02       Impact factor: 3.989

Review 2.  Advances in Liver Cancer Stem Cell Isolation and their Characterization.

Authors:  Lu Liu; Jürgen Borlak
Journal:  Stem Cell Rev Rep       Date:  2021-01-11       Impact factor: 5.739

3.  Ursolic Acid Accelerates Paclitaxel-Induced Cell Death in Esophageal Cancer Cells by Suppressing Akt/FOXM1 Signaling Cascade.

Authors:  Ruo Yu Meng; Hua Jin; Thi Van Nguyen; Ok-Hee Chai; Byung-Hyun Park; Soo Mi Kim
Journal:  Int J Mol Sci       Date:  2021-10-25       Impact factor: 5.923

Review 4.  Aldehyde Dehydrogenase 2 as a Therapeutic Target in Oxidative Stress-Related Diseases: Post-Translational Modifications Deserve More Attention.

Authors:  Jie Gao; Yue Hao; Xiangshu Piao; Xianhong Gu
Journal:  Int J Mol Sci       Date:  2022-02-28       Impact factor: 5.923

5.  An EHMT2/NFYA-ALDH2 signaling axis modulates the RAF pathway to regulate paclitaxel resistance in lung cancer.

Authors:  Wenjing Wang; Jianmin Wang; Shuai Liu; Yong Ren; Jingyu Wang; Sen Liu; Wei Cui; Lina Jia; Xing Tang; Jingyu Yang; Chunfu Wu; Lihui Wang
Journal:  Mol Cancer       Date:  2022-04-27       Impact factor: 27.401

Review 6.  The role of ALDH2 in tumorigenesis and tumor progression: Targeting ALDH2 as a potential cancer treatment.

Authors:  Hong Zhang; Liwu Fu
Journal:  Acta Pharm Sin B       Date:  2021-02-11       Impact factor: 11.413

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.